



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: ☒ RT-SHIV Virus

Catalog Number: 11342

Lot Number: 060841

Release Category: E

Provided: 1 vial of cell-free virus, $10^{3.3}$ TCID₅₀/mL.

Propagation: Virus was propagated in CEMx174 cells.

Description: SIV_{mac239} with the Reverse Transcriptase replaced with that of HIV-1 clone HXBc2.

Special Characteristics: Contains a T to C substitution at position 8 of the SIV tRNA primer binding site that improves replication (Soderberg et.al., 2002)

Recommended Storage: Liquid Nitrogen

Contributor: Drs. Thomas North and Joseph Sodroski

References:

T. W. North, K. K. Van Rompay, J. Higgins, T. B. Matthews, D. A. Wadford, N. C. Pedersen and R. F. Schinazi. (2005). Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. *J Virol*, 79(12), 7349-54. doi:10.1128/JVI.79.12.7349-7354.2005 [PUBMED](#)

K. Soderberg, L. Denekamp, S. Nikiforow, K. Sautter, R. C. Desrosiers and L. Alexander. (2002). A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. *J Virol*, 76(11), 5803-6. [PUBMED](#)

K. Uberla, C. Stahl-Hennig, D. Bottiger, K. Matz-Rensing, F. J. Kaup, J. Li, W. A. Haseltine, B. Fleckenstein, G. Hunsmann, B. Oberg and et al. (1995). Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: RT-SHIV Virus from Dr. Thomas North and Dr. Joseph Sodroski." Also include the references cited above in any publications.

Recipient must not use or incorporate the reagent for commercial purposes.

Last Updated:

May 08, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.